5-MAPB: Benzofuran Entactogen Toxicity, Seizures & Serotonin Risk

5-MAPB: Benzofuran Entactogen Toxicity, Seizures & Serotonin Risk

Quick answer

5-MAPB is a benzofuran stimulant-entactogen often discussed as an MDMA-like research chemical.

Confirmed human toxicity has included hypertension, rapid heart rate, sweating, hyperthermia, tremor, hyperreflexia, clonus, agitation, hallucinations, convulsions and reduced consciousness.

That is a much more useful safety signal than subjective claims that it is “smoother” than MDMA.

Confirmed acute intoxication

A published clinical case involved analytically confirmed 5-MAPB exposure in a previously healthy adult.

The observed syndrome included both sympathomimetic and serotonergic features.

The case demonstrates that severe toxicity can involve neurological, cardiovascular and temperature-regulation systems at the same time.

Fatal co-intoxication evidence

A later forensic report identified 5-MAPB in a fatal co-intoxication with alpha-methyltryptamine and additional drugs.

Because multiple substances were present, the paper does not prove that 5-MAPB alone caused the death.

It does, however, add to the evidence that 5-MAPB appears in high-risk polysubstance contexts.

Serotonin toxicity warning signs

Concerning symptoms include:

• rising body temperature;
• agitation and confusion;
• heavy sweating;
• tremor;
• hyperreflexia;
• clonus;
• muscle rigidity;
• seizure.

Severe serotonin toxicity requires urgent medical assessment.

Why MDMA comparisons have limits

A chemical can share transporter activity with MDMA while differing in duration, receptor profile, metabolism and toxicity.

Without controlled comparative human trials, statements such as “safer MDMA” are not evidence-based.

Related evidence

• 6-APB evidence review
• Benzofuran entactogens
• Synthetic cathinones
• Research chemicals & NPS evidence map

Bottom line

5-MAPB has documented severe human toxicity but little controlled human pharmacology.

That combination is exactly why a friendly online reputation should not be treated as a safety profile.

Why the human evidence for 5-MAPB needs careful interpretation

A useful review of 5-MAPB has to separate confirmed exposure from assumed exposure. Analytical identification can establish that a compound was present, while a clinical case describes what happened to one person under a specific set of circumstances. Neither alone tells us how common an adverse effect is. Laboratory receptor or animal studies add mechanistic detail, but they do not supply a human safety threshold. Keeping those layers separate prevents a thin evidence base from turning into an invented potency chart.

Why product identity matters as much as the drug name

Entactogen and psychedelic RCs can be sold as powders, crystals, capsules, tablets, blotters, or products marketed under a more familiar name. Visual appearance cannot distinguish 5-MAPB from a related analogue, and a seller's label does not establish purity or concentration. Analytical misidentification can also happen when laboratories do not have the right reference material or include the relevant compound in a screening panel.

That uncertainty changes harm interpretation. If an exposure produces unexpectedly intense stimulation, prolonged confusion, severe overheating, or loss of consciousness, assuming the product is “just 5-MAPB” can delay recognition of a substitution or mixture.

Red flags that need medical attention

Severe hyperthermia, seizure, collapse, chest pain, very abnormal heart rate or blood pressure, persistent unconsciousness, extreme agitation, or rapidly worsening confusion should not be written off as an expected entactogen or psychedelic effect. These findings may reflect direct toxicity, an interaction, dehydration/overheating, a substituted compound, or another medical emergency.

Serotonergic or stimulant-like drugs can become harder to interpret when combined with MAO inhibitors, other entactogens, stimulant cathinones, or multiple serotonergic substances. A missing compound-specific interaction trial is an evidence gap, not a guarantee of safety.

What is still missing

For 5-MAPB, important gaps can include controlled human pharmacokinetics, uncommon adverse-event frequency, interaction studies, active-metabolite relevance, and longer-term outcomes. Case reports can establish that a problem is possible; they cannot tell us how often it happens among all users.

Future updates should become more specific only when better human evidence supports that precision. Until then, the evidence grade remains conservative and this page avoids recreational dose ranges or “equivalent” conversions.